HTA50 A Reanalysis of Canada's Drug Agency (CDA) Reports: Do Conclusions from Cost-Effectiveness Analyses Using Quality-Adjusted Life-Years (QALYs) Hold When Evaluating with Equal Value of Life-Years Gained (evLYG)?
Abstract
Authors
Hsin-Yun Yang Liga Bennetts Emna Abdennadher Victor Genestier